Tirzepatide: selected references HeartPep literature library, reviewed 2026-11-20 https://heartpep.com/us/research/library/tirzepatide 1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa2206038 PMID: 35658024 Source: https://pubmed.ncbi.nlm.nih.gov/35658024/ Verification: Abstract / bibliographic record. 2. Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa2416394 PMID: 40353578 Source: https://pubmed.ncbi.nlm.nih.gov/40353578/ Verification: Abstract / bibliographic record. 3. Aronne LJ, Sattar N, Horn DB, et al.; SURMOUNT-4 Investigators (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. DOI: https://doi.org/10.1001/jama.2023.24945 PMID: 38078870 Source: https://pubmed.ncbi.nlm.nih.gov/38078870/ Verification: Abstract / bibliographic record. 4. Del Prato S, Heine RJ, Pérez Manghi FC, et al. (2026). Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial Annals of Internal Medicine. DOI: https://doi.org/10.7326/ANNALS-25-05602 PMID: 42184419 Source: https://pubmed.ncbi.nlm.nih.gov/42184419/ Verification: Abstract / bibliographic record. 5. Kelly AS, Pamidipati KC, Rachmiel M, et al. (2026). Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial JAMA. DOI: https://doi.org/10.1001/jama.2026.23420 PMID: 43035096 Source: https://jamanetwork.com/journals/jama/fullarticle/2856796 Verification: Full text. 6. Editorial Office (2026). Erratum: Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement Translational Cancer Research. DOI: https://doi.org/10.21037/tcr-20262-11 PMID: 42997917 Source: https://tcr.amegroups.org/article/view/127274/html Verification: Full text. 7. Aubrac G et al. (2026). Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation Diabetes, Obesity and Metabolism. DOI: https://doi.org/10.1111/dom.71550 PMID: 43010688 Source: https://pubmed.ncbi.nlm.nih.gov/43010688/ Verification: Abstract / bibliographic record. 8. Doma M et al. (2026). Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes American Heart Journal Plus: Cardiology Research and Practice. DOI: https://doi.org/10.1016/j.ahjo.2026.101003 PMID: 43022342 Source: https://www.sciencedirect.com/science/article/pii/S2666602226002934 Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.